Skip to main content

Site notifications

MS2-STEP MS Health Pty Ltd

Product name
MS2-STEP
Accepted date
Sep-2025
Active ingredients
mifepristone, misoprostol
Proposed indication
MS-2 Step (mifepristone and misoprostol) is proposed for females of childbearing age for:

* ending a pregnancy within the first 70 days. It is recommended that an ultrasound is performed to check how far along the pregnancy is (up to 70 days). If an ultrasound can’t be done, extra care is needed.
* medical management of a miscarriage within the first 70 days (based on an ultrasound instead of the last period).

An ultrasound can also help make sure the pregnancy isn’t ectopic (outside the womb).
Application type
C (new indication)
Publication date
Sep-2025